Mainz Biomed Files 6-K with October Press Release
Ticker: MYNZ · Form: 6-K · Filed: Oct 21, 2024 · CIK: 1874252
| Field | Detail |
|---|---|
| Company | Mainz Biomed N.V. (MYNZ) |
| Form Type | 6-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, press-release
TL;DR
Mainz Biomed dropped an Oct 21 press release via 6-K, following up on their Q2 financials from Oct 18.
AI Summary
Mainz Biomed N.V. filed a Form 6-K on October 21, 2024, to furnish a press release dated October 21, 2024. This follows their previous disclosure on October 18, 2024, which included their Management's Discussion and Analysis and unaudited financial statements for the six months ended June 30, 2024.
Why It Matters
This filing provides updated information and financial statements, allowing investors to assess the company's performance and financial health for the period ending June 30, 2024.
Risk Assessment
Risk Level: low — This is a routine filing providing previously disclosed information and a press release, not indicating new material events or significant financial changes.
Key Players & Entities
- Mainz Biomed N.V. (company) — Filer of the Form 6-K
- October 21, 2024 (date) — Date of the press release and filing
- October 18, 2024 (date) — Date of previous disclosure
- June 30, 2024 (date) — End of the financial reporting period
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to furnish a press release dated October 21, 2024, and it follows up on the company's previous disclosure of its Management's Discussion and Analysis and unaudited financial statements for the six months ended June 30, 2024.
When was the press release furnished as part of this filing dated?
The press release furnished as part of this filing is dated October 21, 2024.
What financial information was previously disclosed on October 18, 2024?
On October 18, 2024, Mainz Biomed N.V. previously disclosed its Management's Discussion and Analysis of Financial Condition and Results of Operations, and unaudited Financial Statements for the six months ended June 30, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at Robert Koch Strasse 50, 55129 Mainz, Germany.
Does Mainz Biomed N.V. file annual reports under Form 20-F or Form 40-F?
Mainz Biomed N.V. files annual reports under cover of Form 20-F.
Filing Stats: 232 words · 1 min read · ~1 pages · Grade level 9 · Accepted 2024-10-21 08:15:22
Filing Documents
- ea0218075-6k_mainz.htm (6-K) — 10KB
- ea021807501ex99-1_mainz.htm (EX-99.1) — 60KB
- 0001213900-24-089097.txt ( ) — 71KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant’s name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Other Events As previously disclosed by Mainz Biomed N.V. (the “Company”) in a Current Report on Form 6-K on October 18, 2024, the Company N.V. made available its Management’s Discussion and Analysis of Financial Condition and Results of Operations, and unaudited Financial Statements each for the six months ended June 30, 2024. Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of dated October 21, 2024, announcing the Company’s results for the six months ended June 30, 2024. Exhibit No. Exhibit 99.1 Press Release dated October 21, 2024 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 21, 2024 By: /s/ William J. Caragol Name: William J. Caragol Title Chief Financial Officer 2